Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An instance of primary ovarian failure that is acquired during the lifetime of the individual.
Biomarker and diagnostic research for acquired primary ovarian failure has been reported in the published literature.
1 FDA-approved treatment is available for acquired primary ovarian failure, including MENOTROPINS (MENOPUR, approved 2004).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
No clinical trials have been registered for acquired primary ovarian failure.
11 publications have been identified in PubMed for acquired primary ovarian failure. Research spans Basic Science / Preclinical (36%), Review / Meta-Analysis (27%), and Diagnostic / Biomarker (9%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 4 | 36% |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 6:33 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acquired primary ovarian failure
MENOTROPINS |
— |
2004 |
Available |
Gene therapy approaches for acquired primary ovarian failure have been reported in the published literature.
View trials for acquired primary ovarian failure
3 |
27% |
Testing and diagnosis research | 1 | 9% |
Clinical study results | 1 | 9% |
Disease patterns and progression | 1 | 9% |
New treatment approaches | 1 | 9% |
Hanawa S (2026). [PMID: 41843055](https://pubmed.ncbi.nlm.nih.gov/41843055/). *International journal of clinical oncology*. [Clinical Trial Publication]
Geng J (2026). [PMID: 42271342](https://pubmed.ncbi.nlm.nih.gov/42271342/). *Cell Commun Signal*. [Basic Science / Preclinical]
Wang PH (2026). [PMID: 41617339](https://pubmed.ncbi.nlm.nih.gov/41617339/). *Taiwanese journal of obstetrics & gynecology*. [Review / Meta-Analysis]
Singleton AL (2025). [PMID: 39641836](https://pubmed.ncbi.nlm.nih.gov/39641836/). *Journal of assisted reproduction and genetics*. [Epidemiology / Natural History]
Rezaie MJ (2025). [PMID: 41090428](https://pubmed.ncbi.nlm.nih.gov/41090428/). *International journal of fertility & sterility*. [Basic Science / Preclinical]
Wang C (2025). [PMID: 41089402](https://pubmed.ncbi.nlm.nih.gov/41089402/). *Journal of inflammation research*. [Gene Therapy / Novel Therapeutics]
Tan H (2025). [PMID: 40495196](https://pubmed.ncbi.nlm.nih.gov/40495196/). *Journal of ovarian research*. [Diagnostic / Biomarker]
Perera L (2025). [PMID: 39859349](https://pubmed.ncbi.nlm.nih.gov/39859349/). *International journal of molecular sciences*. [Basic Science / Preclinical]
Nguyen QTT (2025). [PMID: 40127787](https://pubmed.ncbi.nlm.nih.gov/40127787/). *Critical reviews in oncology/hematology*. [Review / Meta-Analysis]
Yang Q (2024). [PMID: 39010148](https://pubmed.ncbi.nlm.nih.gov/39010148/). *Journal of ovarian research*. [Basic Science / Preclinical]